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Abstract
Background Multiple sclerosis (MS) imposes high economic costs on society, but the patients and their families have to 
bear some of these costs.
Objective We aimed to estimate the magnitude of these economic costs in Norway.
Method We collected data through a postal questionnaire survey targeting 922 MS patients in Hordaland County, western 
Norway, in 2013–2014; 546 agreed to participate and were included. The questionnaire included clinical and demographic 
characteristics, volume and cost of MS-related resource use, work participation, income, government financial support, and 
disability status.
Results The mean annual total economic costs for the patients and their families were €11,603. Indirect costs accounted for 
66% and were lower for women than for men. The direct costs were nearly identical for men and women. The costs increased 
up to Expanded Disability Status Scale score 6 except for steps between 3 and 4 where it remained nearly constant. The costs 
reduced from EDSS 6 to 8, and increased from 8 to 9. Lifetime costs ranged from €24,897 to €70,021 for patients with late 
disease onset and slow progression, and between €441,934 and €574,860 for patients with early onset and rapid progression.
Conclusion The economic costs of MS impose a heavy burden on the patients and their families. Supplementing the infor-
mation on the cost of MS to society, our finding should be included as background information in decisions on reimbursing 
and allocating public resources for the well-being of MS patients and their families.
Keywords MS · Costs · Patient perspective · EDSS · Global MSSS · Norway
JEL Classification H24 · H40 · H55 · I13 · H31
Introduction
Multiple sclerosis (MS) is a chronic inflammatory disease of 
the central nervous system characterized by demyelination 
and axonal loss, leading to the accumulation of neurological 
functional impairment and disability. The progressive loss 
of functioning may result in a high level of disability, and 
several studies of the costs of MS have shown that it imposes 
high economic costs on society [1–4]. The patients and their 
families have to bear some of the costs, but data on their 
magnitude are limited.
A first partial estimate of the costs of MS to the patients 
and their families appeared in 1984 in an article on opti-
mal financial compensation for people with chronic, disa-
bling diseases [5]. Only three studies have comprehensively 
measured the total economic costs to the patients and their 
families. A study [6] estimated the total annual economic 
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costs to society per patient in the United Kingdom in 1994 
at three levels of disability. The study specified the part 
of the costs borne by the patients and their families, GBP 
6098, adjusted for taxes and government financial support. 
A study in Canada [7] estimated the total annual and life-
time economic costs to society per patient, related to three 
levels of disability in 1995. Lifetime costs were estimated 
assuming the number of years at each disability level for 
an average patient. The costs to the patients and their fami-
lies, CAD 19,850 annually and CAD 362,738 lifetime, were 
specified but not adjusted for government financial support. 
A study in the United States [8] estimated the total annual 
and lifetime economic costs to society per patient in 1994. 
The total lifetime economic costs were estimated assum-
ing constant direct economic costs over time and differing 
indirect costs in four age intervals. The costs to the patients 
and their families, USD 24,121 annually and USD 1,575,200 
lifetime, were specified. Later, studies on the cost of MS to 
the patients and their families have concentrated on direct 
[9–11] or indirect [12–14] costs. None of the above studies, 
except for the United Kingdom study from 1994, included 
income tax effects.
Research [15–20] has shown that economic pressure 
caused by MS has a wide range of serious negative effects 
on the well-being and quality of life of people with MS. 
Negative changes in their role definition include cessation 
of work, loss of self-esteem, feeling of letting their partner 
and children down or being a heavy burden on their partner, 
loss of social contact, and depression. In general, all family 
members are affected through loss of hopes and dreams. 
Although residents of Norway are universally covered by 
the welfare system and thus have equal access to health care 
services, the patients and their families have to bear some 
of the costs. To our knowledge, no study has yet been con-
ducted combining annual and lifetime costs for MS patients 
and their families including direct economic costs and indi-
rect economic costs adjusted for private and public disability 
pension, taxes and government financial support, in relation 
to disability status, and the speed of disease progression.
Objective
We aimed to study the costs of MS from the perspective 
of the patients and their families in Norway, defined as the 
reduction in family disposable income for the general con-
sumption of goods and services caused by MS. We examined 
the annual total (direct plus indirect) economic costs related 




We defined direct economic costs as the out-of-pocket 
costs for MS-related resource use. We defined indirect 
economic costs as the net financial loss of the patients 
and their families resulting from reduced work participa-
tion caused by MS, minus government financial support.
Terms
Previous studies of the costs of MS have often used the 
Expanded Disability Status Scale (EDSS) [21] to express 
MS severity in addition to disability status. Our study 
needed a more precise notation. In this article, EDSS 
measures disability status. The Multiple Sclerosis Sever-
ity Score (MSSS) measures relative disease severity and 
the Global MSSS table disease progression [22].
We collected our information through a postal question-
naire survey sent to all MS patients (n = 922) in Hordaland 
County with a known address in August 2013, who had 
received a definite MS diagnosis according to the Poser 
[23] or McDonald [24] criteria. Two postal reminders were 
sent out in January and March 2014.
Questions were on demographic and clinical characteris-
tics, and direct and indirect economic costs. Demographic 
and clinical questions covered sex, age at time of survey, age 
at disease onset and at first symptom, employment, level of 
education, and self-assessed disability status. General infor-
mation on education, wages, and taxes was available from 
Statistics Norway and Norway’s tax authorities.
Self-assessed disability status was measured by 11 writ-
ten health status descriptions that could be allocated to 10 
full-points [1] on the EDSS. The patients indicated the 
description that described their own health status best. 
EDSS is the most commonly used disability status scale 
in MS research and includes eight functioning systems: 
pyramidal function, cerebellar function, brainstem func-
tion, sensory function, bladder and bowel function, visual 
function, and mental function. The original EDSS scale 
contains 11 full-point and 9 half-point levels of increas-
ing disability [0 (no symptoms or signs), 1.0, 1.5, 2.0, 
2.5–9.0, 9.5, and 10 (meaning dead)]. In our study, all 
half-point levels were collapsed with the full-point level 
below. Full-point level 10 (death) was excluded. The dis-
ability description in the collapsed list of disability levels 
that the patients indicated described their disability status 
best was used as the patient’s self-assessed EDSS level.
Questions on direct economic costs included volumes 
and costs to the patients and their families of MS-related 
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resource use. The questions on volumes were on pre-
defined resources, similar to a questionnaire validated in 
earlier studies of the costs of MS to European societies [25, 
26]. All health resources routinely used by MS patients 
were included. Also, “Other” questions were added to each 
health resource category. We added questions on the cost 
of the use to the patients and their families to the questions 
on the volumes, as in previous analyses [1, 10]. To get a 
complete picture of the consumption of health resources 
caused by MS, the patients were instructed to include any 
MS-related health resource use, and also resource use for 
which the patients and their families did not directly bear 
the cost. Finally, we added questions on MS-related costs 
to clothing, nutrition, and traveling or vacation. Table 1 
lists the health resource use covered by the questionnaire. 
Figure 1 shows an excerpt from the questionnaire. The 
patients were instructed to include all costs resulting from 
the use of health resources, such as transport and other 
related costs. The Norwegian Health Economics Admin-
istration regulates payment for the use of health resources. 
The use of approved health resources related to chronic 
diseases is free of charge after the out-of-pocket payments 
for such health resources exceed a threshold of about €250 
each year. For the transport and other related costs, special 
rules apply. These costs are not automatically reimbursed. 
The patients must actually apply for reimbursement of the 
costs. The process is circumstantial. There are also limi-
tations in the regulation of reimbursement of such costs. 
Costs are reimbursed for less than 30% of the transports. 
In practice, therefore, patients most often cover transport 
and other related costs irrespective of whether the €250 
ceiling has been reached for the use of approved health 
resources. Therefore, the annual direct medical costs to 
the patients and their families may exceed the €250 ceil-
ing. If patients reported purchasing or being provided with 
such resources, but did not provide a corresponding cost, 
we assumed that the threshold for the out-of-pocket pay-
ments for the use of health resources had been exceeded 
and that there had been no transport or other related costs, 
and assumed zero payment. This may have underestimated 
these costs. In the sensitivity analysis, we estimated the 
effect on total economic costs of inputing the mean costs 
for the patients using the resource instead of zero. MS 
patients may also have MS-related costs for medication, 
nutrition, household services, clothing, traveling, stays in 
rehabilitation institutions, equipment and mobility adapta-
tions of a dwelling, and a car that are not funded or only 
partly funded by the Norwegian Health Economics Admin-
istration. If patients reported purchasing or being provided 
with such resources, but no actual outlays, the average 
filled-in amounts for the patients using the resource were 
imputed.
Table 1  Direct economic cost items
Physicians in private practice
 Visits to general practitioners
 Visits to specialist physicians
 Home visits
 Contact by telephone etc.
Physicians in hospital
Nurses
 Visits to nurses at office
 Home visits
 Contact by telephone etc.














 Household services (please specify)
 Other forms of assistance (please specify)
Institutionalization
 Bed-days in hospital
 Outpatient stays in hospital
 Rehabilitation stays
 Stays in nursing homes etc.
 Stays in other institutions (please specify)
Drugs and medication
Prescription drugs (including disease-modifying drugs) (please 
specify)
 Non-prescription drugs (please specify)
 Alternative medication (please specify)
Investments
Adaptation of dwelling









 Stairlift with a sitting chair
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The recall period for MS-related resource use and costs 
was 1 month. An exception was a 1-year recall period for 
questions on equipment and mobility adaptations that are 
typically purchased by or provided to MS patients only 
once or a few times during the course of disease (adapting a 
dwelling or a car, ramps, lifts, wheelchairs, walkers, canes, 
crutches, and other helping aids).
The questions on indirect economic costs were on the 
patient’s income, disability pension percentage, government 
financial support, and reduced work hours for family mem-
bers related to the MS. The recall period was 1 month except 
for a 1-year recall period for income.
We aimed to estimate the cost of MS to the patients and 
their families, as opposed to the cost of illness to MS patients 
and their families. Therefore, the respondents were informed 
to include only resource use and reduced work hours caused 
by their MS, as in previous cost of MS studies [25, 26].
No data were censored. The first author (BS) reviewed 
all returned questionnaires. All reported volume and cost 
figures were considered to be within realistic and not pre-
defined limits. Thirteen patients did not return the ques-
tionnaire, but e-mailed or telephoned that their MS caused 
no symptoms or practical limitations. This corresponds to 
EDSS 0 in the questions on self-assessed EDSS in the ques-
tionnaire: “I have no problems and no limitations”. Their 
EDSS level was, therefore, set at 0. In accordance with the 
description, these patients should not be expected to answer 
yes to the questions if they had used any of the resources 
listed in Table 1. Their MS-related use of health resources 
and associated costs were set at zero. Similarly, these 
patients should not be expected to report any MS-related 
reduction in work participation, and their occupational status 
was set at “fully employed”.
Four patients were institutionalized and unable to com-
plete the questionnaire. Their EDSS score was set at 9, and 
their only MS-related direct cost was set to payment for the 
institution. Institutionalized people in Norway do not pay 
explicitly for food, drugs, and necessary health services. For 
stays shorter than 60 days, they are charged a fixed daily 
rate. For stays exceeding 60 days, they are charged a part 
Table 1  (continued)












Fig. 1  Excerpt on institutionalization from the questionnaire
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of their annual after-tax income, typically about €14,458 
in 2013 (information from the Department of Health and 
Care, Municipality of Bergen, Hordaland County). This 
amount, reduced by €3614 for meals free of charge, was 
entered as the only cost of their resource use related to MS. 
In addition, an estimated after-tax average loss of income 
of €14,796 (information from Statistics Norway and Nor-
way’s tax authorities) was added for institutionalized MS 
patients younger than the formal retirement age of 67 years 
in Norway.
We entered the reviewed and corrected information into 
a model programmed in Excel. The model calculated the 
annual direct economic costs for each respondent and their 
family by summing up the direct cost items, the mean costs 
for the patients using the resource in the recall period, and 
the mean annual cost for all respondents taking into account 
the proportion of patients having used the resource in the 
recall period. The costs that had been reported for a 1-month 
recall period were annualized by multiplying by 12.
Multiplying the reported cost of 1 month’s use by 12 may 
not reflect the annual costs of use for individuals. For the 
responding group, 1 month’s resource use and costs multi-
plied by 12 will approximate the costs.
The model calculated the indirect economic costs as each 
patient’s disability pension percentage multiplied by the dif-
ference between the mean net income for employed men 
and women in Hordaland County with the same distribu-
tion by education levels as the respondents, and the mean 
reported net income for the men and women in our study 
with a reported disability pension percentage of 100%. We 
subtracted government financial support. Finally, the model 
calculated the indirect economic costs of a family member’s 
reduced work hours because of the MS as the fraction of 
reduced work hours, multiplied by the mean net income for 
Hordaland County residents. The cost estimates reflect the 
price level during the period from September 1, 2013, to 
April 30, 2014, when the questionnaires were completed. 
Prices increased by 1.3% in Norway during this period.
Comparison of means of unrelated samples and linear 
regression analysis were used to estimate the potential effect 
on total economic costs of differences in age and gender 
proportions between the responders and non-responders.
Costs during the first 30 years after disease onset
To estimate the MS-related economic costs to the patients 
and their families during the first 30 years after disease 
onset, we combined our annual cost estimates with infor-
mation on progression in the Global MSSS table. The 
MSSS measures relative disease severity by comparing 
individual EDSS scores with the distribution of EDSS in 
patients who have had MS for the same duration of time. 
The MSSS scores range from 0.00 to 9.99 and can be split 
into ten deciles, from 0.00–0.99 to 9.00–9.99 of increasing 
relative disease severity. The Global MSSS table shows 
the MSSS scores of patients on each EDSS level each of 
the first 30 years after disease onset in 9892 MS patients 
in Europe and Australia, and how the MSSS deciles pro-
gressed to higher EDSS scores during the period. The 
Global MSSS table shows the progression of the groups 
of patients each year with MSSS score in each decile of 
relative disease severity, but basically not the progression 
of individual patients. Individual patients’ MSSS scores 
may shift between different MSSS deciles during the 
period, but the stability of a person’s MSSS score over 
time was also shown in the European study, with mean 
and 80% range for changes over 5, 10, and 15 years. The 
mean change in MSSS was about zero. The 80% range 
for change in the MSSS was about ± 2.0, considerably 
less than ± 5.5, which would be expected if scores were 
taken at random, reflecting the moderate-to-strong correla-
tion between MSSS measurements made at different time 
points on the same patient [22, 27].
We delineated our analysis of the 30-year costs to the 
patients and their families to (possibly hypothetical) patients 
with MSSS scores in the same decile of relative disease 
severity throughout the period. For these patients, ten cost 
intervals, one interval for patients with MSSS score in the 
same of the ten deciles of relative disease severity, can be 
estimated. Patients with higher MSSS scores reach higher 
EDSS scores earlier than patients with lower MSSS scores, 
i.e., they progress more rapidly, revealing increasing speed 
of progression with increasing MSSS scores.
We estimated 30-year costs for patients with disease onset 
at 32 years of age (the mean age at disease onset for the 
respondents) by substituting their EDSS levels each year 
according to the Global MSSS with the estimated annual 
total economic costs for the EDSS score. Due to the algo-
rithm used to calculate MSSS scores, scores are missing for 
patients with MSSS score in some deciles of relative disease 
severity some years. Where MSSS scores were missing for 
the first year after disease onset, we conservatively assumed 
the EDSS score for the MSSS score below for our cost calcu-
lations. Where MSSS scores were missing for later years, we 
used the EDSS score for that MSSS score the preceding year.
We prepared “optimistic” and “pessimistic” estimates. 
Patients with MSSS score in a given decile of relative dis-
ease severity may be distributed on more than one EDSS 
score each year. In these cases, we used the lowest EDSS 
score for calculating the “optimistic” cost estimate (from the 
perspective of the patients and their families) and the highest 
score for the “pessimistic” estimate. In the Global MSSS 
table, patients with MSSS scores between 0.00 and 0.99, 
for example, 20 years after disease onset, are distributed on 
EDSS 0, 1.0, 1.5, and 2.0 (EDSS levels 0, 1, and 2 in our 
collapsed list of disability levels). We used the estimated 
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cost for patients at EDSS 0 for our optimistic estimate and 
the cost for patients at EDSS 2 for the pessimistic estimate.
The amounts were discounted to account for differential 
timing of costs and summed up.
Lifetime cost
Thirty years is the period after disease onset for which 
empirical information on disease progression exists. The 
duration of the disease for individual patients varies with 
age at disease onset and may be longer than 30 years. The 
sensitivity analysis estimated the lifetime costs for patients 
with disease onset at 21 and 43 years of age (one SD in 
each direction from the mean age at disease onset). The cost 
estimates for years further than 30 years from disease onset 
are based on four assumptions: no further progression later 
than 30 years from disease onset, retirement age 67 years, no 
MS-related income loss after retirement, and life expectancy 
75 years for MS patients.
In the literature, the recommended discount rates to 
account for the differential timing of costs vary [28, 29]. 
We used a real discount rate of 3% annually to the year of 
disease onset. The sensitivity analysis shows the effect on 
the total economic costs to the patients and their families of 
using nominal values and a 5% discount rate.
The Data Protection Officer of Haukeland University 
Hospital approved the study. We performed the statistical 
analysis using IBM SPSS Statistics version 22.
Results
Demographics
Of the 922 MS patients with a known address and a defi-
nite diagnosis in Hordaland County in August 2013, 583 
responded. Thirty-seven patients refused to participate and 
339 did not respond; 546 patients returned a completed ques-
tionnaire or provided required information by mail or phone, 
giving a response rate of 59%, of which 68% were women. 
The respondents’ mean age at time of survey was 53.2 years 
(± 12.9). The mean age at diagnosis was 38.3 years (± 11.4), 
and the age at the first symptom was 32.2 years (± 10.9). The 
median self-assessed EDSS score was 3.0 (IQR: 4), and the 
mean score was 3.4 (± 2.4). A total of 45% reported that 
they were fully (31%) or partly (14%) employed. Among 
the respondents, 12% had only primary or lower secondary 
school, 34% upper secondary school, and 43% had univer-
sity education: 26% for up to 4 years and 17% for more than 
4 years. Table 2 summarizes the clinical and demographic 
data.
The respondents had more women (not statistically 
significant) and a higher mean age (P = 0.003) than the 
non-respondents.
Annual direct economic costs
Direct medical costs
Direct medical costs include the costs of drugs, ambulatory 
care, and institutionalization.
The mean annual cost of drugs and complementary or 
alternative medication was €565. The cost of prescription 
drugs dominated at €297. Altogether 69% of the patients 
received prescription drugs during the 1-month recall 
period. Forty percent of the patients received disease-modi-
fying treatment (Table 3). The Norwegian Health Economics 
Administration pays the full cost of disease-modifying treat-
ment. The patients have transport costs for some treatments.
The mean annual cost for ambulatory care was €375. A 
total of 24% had received ambulatory care by a physician in 
hospital, mainly neurologists, in the 1-month recall period, 
and 23% by a general practitioner. Home visits by a nurse 
had been received by 5%, and 32% had visited a physiothera-
pist; 0.6% a psychologist; 1.1% a chiropractor; and 0.7% had 
visited an acupuncturist. The main cost of €78 was for physi-
otherapy visits, mainly because of frequent visits, on average 
22 per year. In general, physiotherapy was free of charge for 
MS patients in 2013–2014 in Norway, but they often paid the 
transport costs. The cost of visits to physicians in hospital 
(€74) was close to the cost of visits to a physiotherapist. A 
total of 5% visited other professionals, mainly for facilitated 
physical training and “alternative” treatments.
The mean annual cost of institutionalization was €294. 
The proportion of patients reporting that they had been 
hospitalized in the 1-month recall period was 3%, and 7% 
reported outpatient hospital stays. Another 4% received 
rehabilitation and 2% stayed in a nursing home. The far high-
est annual cost was €170 for stays in a nursing home, where 
patients are charged about 80% of their net income after 
some deductions for stays longer than 60 days.
The mean annual direct medical costs amounted to €1234.
Direct non‑medical costs
The direct non-medical costs include adaptations and equip-
ment, assistance, and MS-related costs for clothing, nutri-
tion, and traveling or vacation.
The mean annual cost of mobility adaptations, helping 
aids, and equipment was €1755 (Table 4). In the 1-year 
recall period, 5% of the patients had made mobility adapta-
tions to their dwelling, 5% had purchased or been provided 
with an electric wheelchair, 4% with an electric scooter, 
and 6% with an adaptation of a car. The cost of mobility 
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adaptations of a dwelling comprised the highest cost: 
€1482. Mobility adaptations of a dwelling are expensive, 
and the Norwegian Health Economics Administration does 
not generally pay for them.
The mean annual cost of assistance was €461: 4% had 
received services from a personal assistant in the 1-month 
recall period, 20% had purchased or been provided with 
household services, mainly house cleaning, and 6% other 
forms of assistance. Household services costs: €379.
The mean annual MS-related costs for clothing, nutri-
tion, and traveling or vacation were €481. Costs in the 
1-month recall period were reported by 11, 10, and 13% 
of the patients, respectively.
In total, the mean annual total direct non-medical 
costs were €2696, and thus the mean total annual direct 
economic costs were €3931 in 2013–2014: €3934 for 
women and €3924 for men (Table 5).
Annual indirect economic costs
We calculated annual indirect economic costs based on the 
patients’ MS-related net loss of income from work related 
to MS minus net public and private disability pension and 
government financial support, plus the net loss of income 
of family members related to the MS.
A total of 39% of the patients received 100% disability 
pension, and 14% reported various degrees of disability 
from 20 to 90% (Table 2), giving mean annual indirect 
costs of €6863 (Table 5). In addition, 24 patients (4%) 
reported that another family member had an average 40% 
reduced working hours because of the MS in the 1-month 
Table 2  Clinical and 
demographic data for the 546 




Characteristics n Proportion (%) or mean (± SD or IQR)
Respondents Non-respondents
Sex
 Male 176 32% 132 35%
 Female 370 68% 244 65%
Mean age at time of survey (years) 53.2 (± 12.9) 50.7
Mean age at  diagnosisa (years) 38.3 (± 11.4)






  EDSS 0–3 314 57.5%
  EDSS 4–6 165 30.2%
  EDSS 7–9 63 11.5%
  Unknown 4 0.8%
Employmenta
 No reduction due to MS 168 31%
14% Part-time due to MS 74
 Out of work due to MS 213 39%
 Retired 62 11%
 Unknown 29 5% Population
Educationa Hordaland county
 Primary and lower secondary school 64 12% 26%
 Upper-secondary school 185 34% 43%
 University: < 4 years 142 26% 23%
 University: > 4 years 93 17% 8%
 Unknown 62 11% –
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Table 3  Direct medical costs (euros)a
a Cost numbers are not only the costs of the resource but also other costs related to the resource consumption
b Recall period one month
Number and 
proportion (%) of 
patients using the 
resource in the 
recall period
Mean quantity in 
the recall period 
for the patients 
using the resource
Mean unit cost Mean cost in the recall period for 




















123 (23) 1.4 17.2 24.5 33.8 3.7 66.2
 Specialist physi-
cians
13 (2) 1.6 24.0 38.4 47.4 0.5 11.0
 Home visits 6 (1) 1.5 10.5 15.7 24.3 0.2 2.0
 Contact per 
telephone etc.
25 (5) 3.4 0.6 1.9 5.0 1.9 1.7
 Physicians in 
hospitals
129 (24) 1.4 18.6 26.0 29.3 4.0 73.7
Nurses 20.6
 At office 20 (4) 1.3 15.8 20.6 36.8 0.6 9.1
 Home visits 29 (5) 70.2 0.2 16.6 89.5 46.3 10.5
 Contact per 
telephone etc.
38 (7) 2.2 0.5 1.2 6.3 1.8 1.0
Visits to other 
professionals
199.8
 Physiotherapists 177 (32) 5.6 3.6 20.1 53.1 21.6 78.4
 Psychologists 3 (0.6) 1.0 112.4 112.4 194.1 0.1 7.4
 Chiropractors 6 (1.1) 0.9 121.2 109.1 67.4 0.2 14.4
 Acupuncturists 4 (0.7) 7.8 41.7 325.3 140.3 0.7 28.6
 Other 29 (5) 3.8 29.3 111.3 184.1 2.4 71.0
Institutionalization 293.8
 Hospitalization 17 (3) 7.0 1.3 9.2 30.0 2.5 3.5
 Outpatient hospi-
tal stays
40 (7) 2.0 11.2 22.4 29.9 2.0 19.7
 Nursing home 
etc.
10 (2) 27.0 28.7 774.1 483.1 5.9 170.2
 Rehabilitation 21 (4) 21.0 10.0 210.0 469.2 9.5 96.9









377 (69) 34.5 61.0 295.3
 Disease-modify-
ing treatment
216 (40) 4.7 11.8 1.8
 Non-prescription 
drugs
108 (20) 42.2 65.3 100.3
 Alternative medi-
cation
105 (19) 73.0 86.8 168.0
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recall period, giving estimated mean annual indirect eco-
nomic costs of €809. Reduced work participation due to 
sickness and rehabilitation absences causes no economic 
cost to Norwegian patients and their families as they 
receive full compensation during such absences.
The mean annual total indirect economic costs were 
€7672; €9989 for men and €6544 for women.
Table 4  Direct non-medical economic costs (euros)a
a Cost numbers are not only the costs of the resource but also other costs related to the resource consumption
b Recall period 1 year
c Recall period 1 month
Proportion (%) of 
patients using the 
resource in the 
recall period
Mean quantity 
(hours) in the recall 
period for the 
patients using the 
resource
Mean unit cost Mean cost in the 
recall period for the 
patients using the 
resource
Mean quantity per 
year for all patients
Estimated mean 












28 (5) 28,894.1 27,506.8 1481.7
Purchase and adaptation of:
 Car 31 (6) 3513.4 3865.5 199.5
 Electric wheel-
chair
29 (5) 85.7 326.7 4.5
 Electric scooter 22 (4) 677.4 1574.5 27.3




15 (3) 294.8 314.6 8.1
 Safety alarm 18 (3) 200.4 166.9 6.6
 Ramps 7 (1) 447.4 780.2 5.5
 Cane and crutches 38 (7) 33.4 30.7 2.3
 Other helping aids 85 (16) 68.1 168.3 10.4
Assistancec 461.0
  Personal assistant 21 (4) 157.7 0.2 37.7 122.0 73.0 17.3
 Household ser-
vices
110 (20) 6.1 9.3 57.0 278.6 10.7 379.2
 Other forms of 
assistance




 Clothing 62 (11) 108.1 87.4 123.6
 Nutrition 53 (10) 96.4 89.1 112.3
 Traveling and 
vacations
70 (13) 224.1 264.7 344.8
Table 5  Direct, indirect, and total economic costs to patients and 
their families
Cost category Average yearly costs (euros)
Total Women Men
Direct economic costs 3931 3934 3924
Indirect economic costs
 Patients 6863 5942 8871
 Family members 809 602 1118
Total economic costs 11,603 10,478 13,913
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Total economic costs for MS patients and their families
When adding the annual direct (34%) and indirect (66%) 
economic costs, the mean annual total economic costs to the 
patients and their families were €11,603. Direct economic 
costs were nearly identical for women and men. The indirect 
costs were 34% lower for women, mainly because of lower 
salaries when disability pension was granted and because 
women received more government financial support.
The calculated direct economic costs were out-of-pocket 
costs, and we adjusted the indirect costs for tax effects, pri-
vate and public disability pension, and government financial 
support. The calculated total MS-related economic costs, 
therefore, reduced the family disposable income for the gen-
eral consumption of goods and services by its full amount.
The total economic cost increased by €147.2 per year of 
increasing age, starting at €3136. In the sensitivity analy-
sis, we calculated the potential effect of the age difference 
between responders and non-responders on the average total 
economic costs to the patients and their families.
Economic costs related to EDSS score
Direct economic costs increased steadily up to full-point 
EDSS 6, declined from EDSS 6 to 8 before peaking at EDSS 
9 (Table 6). The reduced costs of mobility adaptations of a 
dwelling were the largest item in the reduction from EDSS 
6 to 8. Such adaptations are costly to the patients and their 
families and increasingly rare after patients have reached 
EDSS 6. The increase from EDSS 8 to 9 is explained by 
patients at EDSS 9 more often being institutionalized, where 
they are charged close to 80% of their net income for the 
stay.
Indirect economic costs basically increased up to full-
point EDSS 7, except for a 9% decline between EDSS 3 and 
4 caused by increased government financial support and by 
reduced income loss for family members. The costs were 
reduced by 31% from EDSS 7 to 8, mainly because of a 
higher percentage of retired patients at EDSS 8 (26%) than at 
EDSS 7 (23%). The increase from EDSS 8 to 9 is caused by 
reduced government financial support for patients at EDSS 
9. A total of 67% of the patients at EDSS 9 were institu-
tionalized. Institutionalized patients have limited access to 
government financial support.
The total economic costs increased up to full-point EDSS 
6, except for between EDSS 3 and 4 where they remained 
nearly constant. The costs declined moderately from EDSS 
6 to 7 and more markedly declined from EDSS 7 to 8. They 
then increased from EDSS 8 to 9.
Costs to patients and their families for the first 30 years 
after disease onset
For patients with disease onset at 32 years of age and MSSS 
score in the first decile of relative disease severity through-
out the 30-year period covered by the Global MSSS table, 
the present value of the total estimated 30-year costs was 
between €27,832 and €85,546, discounted at 3% annually. 
For patients with MSSS score in the 10th decile through-
out the period, the estimated costs were between €353,375 
and €437,854. Table 7 gives cost intervals for patients with 
MSSS scores in all the ten deciles of relative disease severity 









EDSS 0 1420 277 1143
EDSS 1 4332 582 3750
EDSS 2 7891 1796 6095
EDSS 3 12,565 2585 9980
EDSS 4 12,526 3480 9046
EDSS 5 16,557 5551 11,006
EDSS 6 22,624 10,994 11,630
EDSS 7 22,330 8815 13,515
EDSS 8 15,100 5780 9320
EDSS 9 22,339 11,875 10,464
Table 7  Total economic cost in euros for the first 30 years after dis-
ease onset: discount rate 3%
Patients with MSS score 
in the:
Cost estimate 30-year cost
1th decile Optimistic 27,832
Pessimistic 85,546
2nd decile Optimistic 108,892
Pessimistic 143,493
3rd decile Optimistic 168,258
Pessimistic 174,192
4th decile Optimistic 203,671
Pessimistic 217,629
5th decile Optimistic 252,050
Pessimistic 260,801
6th decile Optimistic 310,007
Pessimistic 315,746
7th decile Optimistic 337,870
Pessimistic 352,642
8th decile Optimistic 372,518
Pessimistic 385,037
9th decile Optimistic 388,460
Pessimistic 358,845
10th decile Optimistic 353,375
Pessimistic 437,854
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throughout the 30-year period. Because of the decline in 
mean annual total economic costs between EDSS 6 and 8, 
the 30-year costs for patients with MSSS scores in the 7th 
to 10th decile of disease severity are within a relatively nar-
row interval.
We estimated the lifetime costs for patients with dis-
ease onset at 21 and 43 years of age. The estimated life-
time costs to patients with MSSS score in the first decile 
of relative disease severity throughout the course of dis-
ease and disease onset at 43 years of age are estimated 
between €24,897 and €70,021 and between €330,850 and 
€414,718 for patients with MSSS score in the 10th decile. 
For patients with disease onset at 21 years of age, the cor-
responding numbers are between €35,680 and €129,618 
and between €441,934 and €574,860 (Table 8).
Sensitivity analysis
The effect on total economic costs of imputing the mean 
costs for the users of the resource instead of zero costs 
when respondents indicated using a resource, but did not 
state an amount is + 1.4%. (Table 8). The effect of adjust-
ing for differences in age between respondents and non-
respondents is − 1.3%. Finally, the effects on lifetime 
costs of using nominal values and of discounting at 5% 
are shown.
Discussion
We examined the annual total MS-related economic costs for 
the patients and their families during 2013–2014, as meas-
ured by the reduction in family disposable income for the 
general consumption of goods and services caused by MS. 
The mean annual total economic costs were €11,603 per 
patient, including €3931 in direct costs and €7672 in indirect 
costs. The direct costs were similar for men and women. The 
indirect costs were 34% lower for women. The estimated 
present value of the lifetime costs for patients with disease 
onset at 21 years of age was between €35,680 and €129,618 
(discounted at 3%) and between €441,934 and €574,860 for 
patients with MSSS scores in the 1st and 10th decile of dis-
ease severity throughout the course of disease.
Of the three comprehensive studies in the mid-1990s 
on the total annual economic costs to the patients and their 
families, the studies in the United Kingdom and Canada [6, 
7] related the costs to disability levels. The costs increased 
with three broadly defined levels of escalating disabil-
ity in both studies. In our study, the costs increased up to 
Table 8  Sensitivity analysis
Changes in data management Mean total economic costs (€) Change from 
base case (%)
Imputing the mean cost for patients using the resource instead of zero cost where respondents 
have indicated using a resource but not accompanied this by an amount
11,675 + 1.4
Adjusting for differences in age between respondents and non-respondents 11,452 − 1.3
Lifetime cost in euros of patients with MSSS score in the first and 10th decile of disease severity throughout the course of disease, with disease 
onset at 43 and 21 years of age, nominal and discounted at 3 and 5% annually
Discount rate
0 3 5
Disease onset at age 43 years
 First decile of disease severity
  Optimistic 36,019 24,897 20,091
  Pessimistic 113,951 70,021 52,245
 10th decile of disease severity
  Optimistic 476,382 330,850 267,776
  Pessimistic 619,261 414,718 329,553
Disease onset at age 21 years
 First decile of disease severity
  Optimistic 67,536 35,680 25,579
  Pessimistic 289,349 129,618 82,460
 10th decile of disease severity
  Optimistic 814,362 441,934 322,995
  Pessimistic 1,122,594 574,860 407,558
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full-point EDSS 6, except for between EDSS 3 and 4 where 
they remained nearly constant. They declined moderately 
from EDSS 6 to 7 and more markedly declined from EDSS 
7 to 8, and increased from EDSS 8 to 9. If we collapse our 
disability status scores into three broader levels, comparable 
to those in the studies in the United Kingdom and Canada, 
our results also show steadily increasing costs with escalat-
ing disability.
We do not compare the results further. The welfare system 
in the United States, the United Kingdom, and Canada may 
have changed since 1994–1995. Further, differences between 
the estimated costs to the patients and their families based 
on updated cost amounts would have been influenced by the 
choice of indexes to account for inflation, exchange rates 
used for currency conversion, discount rate to account for the 
differential timing of costs, and the definition of “lifetime” 
in the studies. Differences might also have been caused by 
methodological issues such as differences in including and 
valuing cost items, the representativeness of the study popu-
lation, and the methods for collecting and managing data. 
Adjusting correctly for all these factors is impossible. This 
highlights a need for more up-to-date and standardized stud-
ies of the costs of MS from the perspective of the patients 
and their families.
We defined the cost of MS to the patients and their fami-
lies as the reduction in family disposable income for the 
general consumption of goods and services caused by MS. 
Some relevant costs will be obvious. For example, required 
part-payment for consultations, drugs, etc., or the total cost 
of treatments and purchases of nutrition products is not reim-
bursed by the Norwegian Health Economics Administration. 
Some costs will be far less obvious. For example, replac-
ing cloths have been damaged by the wheel chair or spilled 
to while eating, and choosing a more expensive means of 
travel, apartment, or hotel to be able to function well during 
vacations, etc. We aimed to give a complete picture of all 
these costs. The patients were given this information in the 
fill-in guidance to the questionnaire.
Data for cost of illness analysis can be extracted from 
national registries and statistics or collected directly from a 
limited sample of people with illness, usually by question-
naires. Both methods have strengths and weaknesses. Data 
from national registries and statistics are generally objective, 
representative for the population studied and not influenced 
by subjective evaluation. However, national registries and 
statistics may not contain all the information needed for the 
study. The tools to collect data directly from people with 
illness can be tailored to provide all needed information. 
However, the data may be influenced by subjective evalu-
ation and exposed to recall error and error caused by mis-
understanding of questions. In Norway, national registry 
and statistical information on the out-of-pocket costs to the 
patients and their families for MS-related resource use are 
generally not available, and we did not have access to exist-
ing information on indirect costs at the level detail required 
for our study because of Norway’s data protection rules. We, 
therefore, collected our information through a postal ques-
tionnaire survey sent to MS patients in Hordaland County, 
Norway, but made efforts to reduce the potential effects of 
the weaknesses with this approach.
To reduce recall error, the questions on the volumes and 
costs of MS-related resource use and reduced work partici-
pation had mostly a 1-month recall period. The exception 
was a 1-year recall period for resources that are purchased by 
or provided to patients only once or a few times during the 
course of disease, i.e., adapting a dwelling or a car, ramps, 
lifts, wheelchairs, walkers, canes, crutches, and other help-
ing aids.
For resources that are typically purchased by or provided 
to MS patients only once or a few times during the course of 
disease, longer recall periods than 1 year might have been an 
alternative. Whether this would have provided that more cor-
rect cost estimates is uncertain, however, and a 1-year recall 
period for using such resources has been typical in several 
studies of the cost of MS. Further, in Norway, the costs to 
the patients and their families of acquiring all except one of 
these resources, mobility adaptation of a dwelling, are low 
because of large subsidies. They are normally also acquired 
more than once during the course of disease, and choosing 
longer recall periods would probably have affected the total 
cost estimate marginally. A dwelling, however, is most typi-
cally mobility adapted only once, is expensive, and is mostly 
paid for by the patients. As a check on the reporting of this 
dominant direct cost item, the patients who reported adapt-
ing a dwelling were contacted by telephone to verify that 
they had understood and answered the question correctly. 
The answers revealed that in two cases, the adaptation could 
have been made over a longer period than the year before the 
questionnaire was completed. In these two cases, we divided 
the reported cost by two before being included.
To reduce misunderstanding of questions, the questions 
on the volumes and costs of health resources used and on 
reduced work participation were similar to the previous cost 
of MS studies except for questions on MS-related costs to 
clothing, nutrition, and traveling or vacation. These costs 
are well known to MS patients in Norway since government 
financial support can be grated to cover part of the costs.
To reduce subjective evaluations, all questions except 
for one were factual: the number of visits to physiothera-
pists, the out-of-pocket cost of the visits, etc. The excep-
tion was the self-assessed EDSS score. The questions on 
self-assessed EDSS had been tested on a limited sample 
of patients and were well correlated with neurologist-rated 
EDSS scores [1]. The patients were explicitly informed to 
include only resource use caused by their MS. This added 
an extra element of subjective evaluation. For studies of the 
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costs of illness, distinguishing how much of the use of health 
resources and reduced work participation the disease being 
investigated causes from how much other health problems 
cause may be difficult. For MS, however, this is considered 
to be less of a problem, since the effects of MS are rather 
well defined [30], and studies on self-reporting data from 
MS patients have been shown to be highly accurate despite 
potential cognitive difficulties and general recall bias [26].
We delineated our study of the 30-year costs to the 
patients and their families to (possibly hypothetical) patients 
with MSSS scores in the same decile of relative disease 
severity throughout the period. This enabled us to illustrate 
the relation between costs and the speed of disease progres-
sion with the costs of ten schematic, but realistic progression 
paths of increasing speed of progression. Other progression 
paths are possible, but all will have cost estimates in the 
interval between our optimistic estimate for patients with 
MSSS scores in the first decile of relative disease sever-
ity, and the pessimistic estimate for the patients with MSSS 
scores in the 10th decile of relative disease severity. Our 
30-year cost estimates, therefore, span the range of possible 
30-year costs to the patients and their families. The data 
used to develop the Global MSSS reflect the situation in 
2005 for patients with disease onset from 1 to 30 years ear-
lier. The situation in 2005 may not be representative for the 
current situation. The increased use of gradually more effi-
cacious disease-modifying therapies has especially slowed 
the disease progression. Thus, the deciles of relative disease 
severity in an updated Global MSSS have probably shifted 
somewhat to the left, and accordingly changed the cost for 
patients with MSSS scores in most of the deciles. The poten-
tial for reduced costs would have been greatest for patients 
with MSSS scores in the first six deciles. The potential cost 
reductions for patients with MSSS scores in the 7th to 10th 
deciles would have been more limited because of the rela-
tively narrow interval of costs for patients with MSSS scores 
in these deciles. But no data are available today, however, on 
the possibly slowed progression.
In calculating the 30-year and lifetime costs, we incorpo-
rated the costs of adapting a dwelling in the yearly costs at 
each EDSS level. This may have led to overestimating these 
costs for patients who stay longer than average at EDSS 
levels with a high cost of adapting a dwelling, primarily 
patients at EDSS 6 and, to lesser extent, EDSS 5 and 7. 
Ideally, the costs of adapting a dwelling should have been 
incorporated in the cash flows using an incidence-based 
method. For today, however, so many simplifying assump-
tions would have to be made that the adjustments to the 
cash flows would seem unrealistic. The cost of adapting a 
dwelling in our study was the out-of-pocket costs for the 
adaptation. A hidden cost will be a reduced market value 
for the dwelling, since other people neither need nor fancy 
dwellings adapted for people with disabilities. We did not 
include this loss in market value in the costs.
The respondents were significantly younger than the non-
respondents. The sensitivity analysis quantified the effect 
of this on the total cost estimate. The non-respondents may 
also have different MS-related resource use and costs than 
the respondents. We cannot correct our cost estimates for 
the potential effect of this. The response rate in our study 
(59%) is high for a questionnaire-based study of the cost of 
MS. In studies in nine European countries [1], only the one 
for Sweden had a higher response rate (75%) and the other 
ranged between 19 and 52%.
The Global MSSS has been validated for use in compar-
ing the disease progression in groups of patients. Disease 
fluctuations preclude using it to predict the future disability 
of an individual. We used the information on disease pro-
gression in the Global MSSS table to estimate 30-year and 
lifetime costs to the patients and their families for ten groups 
of patients with MSSS scores in the same decile of relative 
disease severity throughout the course of disease.
The data were collected in Hordaland County. One limi-
tation is that the cost effects of the disease in Hordaland 
County may not be representative of the cost effects in other 
parts of Norway. The Norwegian Multiple Sclerosis Com-
petence Centre is located at the Department of Neurology 
of Haukeland University Hospital in Hordaland County, 
and numerous MS studies conducted at the Department 
may increase the contact frequency of the patients to the 
Department. However, epidemiological studies from Horda-
land have shown similar prevalence and characteristics of 
the MS population, and these are comparable to other parts 
of the country [31]. In addition, national surveys of the use 
of disease-modifying therapies have shown that the average 
treatment frequency in Hordaland County has been similar 
to that of the country as a whole [32]. Hordaland County 
has about 10% of the MS patients in Norway and comprises 
both rural and urban areas like most other counties in Nor-
way. This should contribute to making the MS population in 
Hordaland County reasonably representative for the national 
MS population.
Conclusion
It has long been recognized that MS imposes high economic 
costs on society. In Norway, all members of society share 
most of the costs. A part, however, has to be borne by the 
patients and their families themselves. Our study revealed 
that this imposes a considerable economic burden on the 
patients and their families, even in Norway’s welfare state 
with a well-developed social security system. Supplement-
ing the information on the costs of MS to society that has 
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more typically been provided by studies of the costs of MS, 
our finding should be included as background information 
in decisions on reimbursing and allocating resources for the 
well-being of the MS patients and their families.
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